Vaccines Market Worth 48.03 Billion USD by 2021

PUNE, India, August 9, 2016 /PRNewswire/ --

According to a new market research report "Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021", published by MarketsandMarkets, The global market is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021.

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 89 market data Tables and 55 Figures spread through 158 Pages and in-depth TOC on "Vaccines Market"

http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Early buyers will receive 10% customization on this report. 

The major factor driving the growth of this market are high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs.

The report segments this market based on technology, type, disease indication, end-users, and regions. Among the various technologies, the conjugate vaccines segment is expected to account for the largest share of the market. This segment is projected to grow at the highest CAGR from 2016 to 2021. The high growth of this segment can be attributed to the increasing government support for vaccine development and rising company investments.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=1155

On the basis of type, the Vaccines Market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is expected to account for the largest share of the global Vaccines Market in 2016 due to rising prevalence of diseases and increasing government and non-government initiatives for vaccine R&D activities.

Disease indication, included in the Vaccines Market are pneumococcal disease, influenza, diphtheria, tetanus, and pertussis (DTP), hepatitis, rotavirus, varicella, meningococcal disease, polio, measles, mumps, and rubella (MMR), human papilloma virus (HPV) infection, and others. The pneumococcal disease segment is expected to account for the largest share of the global Vaccines Market in 2016. High incidence of pneumococcal infections is driving the growth of this market.